ANI Pharmaceuticals
ANIP
120 hedge funds and large institutions have $293M invested in ANI Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 16 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 33
13% more capital invested
Capital invested by funds: $259M → $293M (+$34.6M)
3.97% more ownership
Funds ownership: 53.33% → 57.3% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 126 → 120 (-6)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
67% less call options, than puts
Call options by funds: $614K | Put options by funds: $1.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$7.05M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.68M |
| 3 |
BlackRock
New York
|
+$3.61M |
| 4 |
Goldman Sachs
New York
|
+$3.47M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.61M |
| 2 |
Renaissance Technologies
New York
|
-$2.49M |
| 3 |
Millennium Management
New York
|
-$1.33M |
| 4 |
Two Sigma Investments
New York
|
-$1.26M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.05M |
ANIP Hedge Fund Activity: Q2 2022 in Review
120 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2022, worth a combined $293M — up 13% from $259M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ANIP and 13 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 52 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $7.05M. The largest seller was Federated Hermes, cutting an estimated $7.61M.
- 120 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2022, down from 126 in Q1 2022.
- Funds reported $293M of ANI Pharmaceuticals stock for Q2 2022, up 13% quarter-over-quarter.
- 13 funds opened new ANI Pharmaceuticals positions in Q2 2022 and 16 closed out, a net change of -3 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2022 was AIGH Capital Management, an estimated $7.05M added.
- The largest ANI Pharmaceuticals seller in Q2 2022 was Federated Hermes, an estimated $7.61M sold.
Based on aggregated 13F filings for Q2 2022.